Cadus Financial Ratios

Cadus Corporation -- USA Stock  

USD 1.59  0.01  0.63%

We suggest you to use analysis of Cadus fundamentals to see if markets are presently mispricing the company. We found twenty-five available fundamental indicators for Cadus Corporation which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Cadus fundamentals including its EBITDA as well as the relationship between Cash Flow from Operations and Retained Earnings . Please also double-check Cadus Corporation Price to Earning to validate the company can sustain itself down the road.Use Cadus to enhance returns of your portfolios. The stock experiences moderate upward volatility. Check odds of Cadus to be traded at $1.749 in 30 days

Cadus Company Summary

Cadus competes with Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Seattle Genetics, Sage Therapeutics, and N/A. Cadus Corporation engages in real estate acquisition, renovation, and construction activities in south Florida. Cadus Corporation was founded in 1992 and is based in New York, New York. Cadus operates under Biotechnology classification in USA and traded on OTC Market.

Cadus Cash Flow from Operations vs Book Value Per Share

Cadus Corporation is rated fourth overall in cash flow from operations category among related companies. It is rated below average in book value per share category among related companies .

Cadus Systematic Risk

The output start index for this execution was six with a total number of output elements of eleven. The Beta measures systematic risk based on how returns on Cadus correlated with the market. If Beta is less then 0 Cadus generally moves in the opposite direction as compared to the market. If Cadus Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cadus is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cadus is generally in the same direction as the market. If Beta > 1 Cadus moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
< 49% 

Chance of Financial Distress

Cadus Corporation has less than 49 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Cadus Thematic Clasifications

Active Ideas That Utilize Cadus
Biotech IdeaBiotechView


Compare Cadus To Peers


Cadus Corporation Executive Managers
Hunter Gary CEO and President and Director
David Blitz CFO, Principal Accounting Officer, Treasurer and Secretary
More Executives

Opportunity Range

March 24, 2018 Opportunity Range